Cardiac Stents

Cardiac stents to cost 2% more as regulator allows prices to be raised

National Pharmaceutical Pricing Authority allows manufacturers to make adjustment for inflation

Use of leadless pacemakers rising; need data on effects, implants: Experts

As the market for leadless pacemakers grows in India, doctors point out definite advantages of the technology for heart disease patients but also call for more data and analyses on its long-term effects. At the same time, researchers have written about the lack of a national registry tracking pacemaker implants, including conventional ones. A pacemaker helps a heart patient control an irregular heartbeat. In November, Abbott, the US-based healthcare and medical devices company, introduced the AVEIR VR single-chamber ventricular leadless pacemaker in India for treating patients having slow heart rhythms. The device has been approved by the Central Drugs Standard Control Organization, Abbott said in a statement. The AVEIR VR device is implanted directly into the heart's right lower chamber (ventricle) through a "minimally invasive, catheter-based procedure from the groin", thereby requiring no surgical cuts to the chest or wires, it said. Doctors consider a 'leadless' pacemaker an

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

New-gen stents help domestic players gain market from foreign players

While foreign players have either withdrawn or shied away from introducing new-generation stents in India post price cap, Indian firms have gone ahead

Government to notify cardiac stent pricing in 15 days

Prices of both metallic and drug-eluting likely to be brought down once notification is announced